Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...
Can you leave a clinical trial early? Learn your rights, what happens if you withdraw, and how to exit safely without affecting your medical care.
Delcath Systems, Inc.’s Q3 revenue was pressured by weak patient starts, but 2026 growth prospects remain strong. Click for ...
Outpatient migration, bispecific adoption, and non-oncology trial expansion are increasing capacity pressure, making flexible ...
New research by Cleveland Clinic and Dyania Health demonstrates how a medically trained large language model system can accurately and efficiently screen electronic medical records (EMRs) to identify ...
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has ...
Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - ...
Q4 2025 Earnings Call March 3, 2026 8:00 AM ESTCompany ParticipantsMathew Schneider - CFO of Clinical Services & ...
As Rare Disease Day approaches, the lessons from recent European launches are clear: success comes from disciplined operating models, disease‑centred engagement, pragmatic evidence strategies, and ...
Non-GBM Product Revenue Expectation -- Expected contribution of $15-$25 million in 2026, compared to $10 million in 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results